Reports

IMV’s 2026 Nuclear Medicine Market Outlook examines nuclear medicine procedure volumes, purchase plans, and buying criteria for future nuclear medicine purchases. Learn how NM administrators feel about their department’s future outlook and how they prioritize their goals in light of industry challenges. The report explores nuclear medicine market trends, including NM procedure volume, installed base…

Immunoassays remain a foundational pillar of the in vitro diagnostics (IVD) landscape, underpinning a broad range of clinical testing applications despite the maturity of many platforms. Their continued relevance reflects both their versatility across disease areas and the steady pace of technological refinement that has sustained growth and clinical adoption over time. This Kalorama Information…

How has AI reshaped life science workflows in the past year? Which AI solutions have emerged as indispensable to researchers and which have fallen short? Do scientists genuinely trust AI-generated results, and how are those perceptions shifting? 

 

The 2026 edition of Perceptions of Artificial Intelligence in the Life Sciences delivers a definitive read on where life science professionals…

The Kalorama Molecular Diagnostics Quarterly Datastream is exclusively available to purchasers of our annual reports: Worldwide In Vitro Diagnostic (IVD) Tests, World Market for Molecular Diagnostics, or Molecular Point-of-Care (mPOC). This quarterly update covers markets detailed in these reports.

PET imaging has grown over the past two decades to become a mainstay in the diagnosis and management of cancer patients. While oncology scans continue to comprise the majority of PET scans, new radiopharmaceuticals offer the promise of increasing the efficacy of PET imaging for cardiology and neurology.

IMV’s 2026 PET Imaging Outlook Summary Report…

The in vitro diagnostics (IVD) industry is a cornerstone of modern healthcare, empowering clinicians to detect disease, monitor health conditions, and guide treatment decisions with precision. As healthcare continues to evolve—driven by rising rates of chronic conditions such as diabetes and cardiovascular disease, along with ongoing and emerging infectious threats—the IVD market is…

The global market for respiratory and non-respiratory IVD panel-based testing is undergoing continued structural evolution. Panel-based tests allow for the simultaneous detection of multiple pathogens and or resistance markers from a single specimen, supporting efficient workflows, faster time to results, and greater diagnostic confidence. Market growth is increasingly driven by broader clinical adoption and expanding…

Molecular point-of-care testing continues to reshape diagnostic workflows by bringing the accuracy of molecular methods closer to the patient. In Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 11th Edition (2025 to 2030), Kalorama Information examines a market that has matured significantly over the past decade while remaining dynamic. Distinctions between true point-of-care and near patient…

The 2025 SDi Global Assessment Datastream is only available to those who have purchased The 2025 Global Assessment Report: The Analytical and Life Science Instrumentation Industry.

Pathology remains fundamental to modern clinical diagnostics, supplying the cellular, tissue, and organ‑level insights that guide disease detection, treatment selection, and patient management. As healthcare becomes more data‑driven and personalized, the value of pathology continues to increase. Advances in imaging, staining, and molecular techniques have improved understanding of how structural changes in tissues relate to…

The molecular diagnostics market remains a powerful growth engine within the global in vitro diagnostics (IVD) industry. Several years after the pandemic, demand continues to expand across infectious disease testing, cancer diagnostics, and transplant applications. Kalorama Information’s World Market for Molecular Diagnostics, 14th Edition delivers a comprehensive, data-driven analysis of this fast-evolving sector, examining the…

The CGT market is evolving rapidly, with billions in investments and thousands of strategic deals shaping its trajectory. Companies that understand the landscape and anticipate future deal trends will have the competitive edge needed to thrive. Whether you are a biotech executive, investor, R&D leader, or regulatory strategist, this report provides data-driven insights to inform…